Boston Scientific (BSX) Q3 2026 Earnings Call Transcript

Boston Scientific (BSX) reported Q3 2026 organic sales growth of 1.5%, missing guidance due to a cybersecurity incident. Q3 adjusted EPS was $0.73, down 3% from guidance. Q4 is expected to see a 1-3% revenue decline and EPS of $0.77-$0.79. Full-year 2026 revenue growth is guided at 4%, with EPS of $3.16-$3.18. The company anticipates challenges in 2027 but plans for growth in 2028-2029, driven by new launches and market expansions.

Original reporting
Published Oct 28, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific (BSX) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The disclosed lower guidance and cyber‑incident impact suggest near‑term downside, but the company highlights restructuring and upcoming product launches for longer‑term growth.

02

Market read

Earnings and guidance update for a large‑cap med‑tech firm, with immediate price implications.

03

What to watch

Long‑term pipeline of new product launches and $25 bn market opportunity by 2030 could offset short‑term headwinds.

Relevance 8/10Novelty 9/10Timing: after‑hours today

Background

Boston Scientific held its Q3 2026 earnings call, providing results and outlook for the remainder of the year.

Company-level read

Ticker impact

$BSXBearishMedium confidence
Context

Q3 adjusted EPS $0.73 and organic sales +1.5% disclosed, with FY 2026 guidance lowered to 4% revenue growth and $3.16‑$3.18 EPS.

Expected impact

downward pressure as investors price in lower revenue growth and cyber‑related headwinds

Evidence & confidence

Guidance below prior expectations and a disclosed cyber incident reducing sales growth by ~300 bps create near‑term downside risk.

Market effects

Medical‑device sector may see broader pressure from cyber‑risk concerns and slower growth guidance.

US med‑tech stocks could face modest pullback in early trading.

International investors in med‑tech may adjust exposure based on the guidance and cyber‑incident fallout.

Counterpoint

If the cyber‑incident is resolved quickly, the company could rebound and exceed guidance, offering upside.

Key entities

  • Boston Scientific

    Medical‑device maker reporting Q3 results and FY guidance.

  • Penumbra

    Target of a pending acquisition by Boston Scientific.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.